According to the Zhitong Finance App, Qingcheng New Pharmaceutical-B (02396.HK) announced interim results for the six months ended June 30, 2026. The group's other revenue and revenue was RMB 999,000, up 59.08% year on year; parent company owners should account for losses of RMB 122 million, up 40.65% year on year; basic and diluted loss of $1.04 per share; proposed interim dividend of HK$0.50 per share.
智通財經·08/14/2026 11:25:11
語音播報
According to the Zhitong Finance App, Qingcheng New Pharmaceutical-B (02396.HK) announced interim results for the six months ended June 30, 2026. The group's other revenue and revenue was RMB 999,000, up 59.08% year on year; parent company owners should account for losses of RMB 122 million, up 40.65% year on year; basic and diluted loss of $1.04 per share; proposed interim dividend of HK$0.50 per share.